Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433210 · ClinicalTrials.gov registry record · NA
A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
A NA study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT02433210 is a NA study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 11 participants.
The verdict
NCT02433210, a NA study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The aim of the study is to confirm the safety and clinical effectiveness of Nipro ELISIO-15H and to compare its performance characteristics and hemocompatibility with those of the commercially available dialyzers in U.S.A., Gambro Polyflux Revaclear and Fresenius F160NRe. 10 stable patients will be dialyzed 3 times/week with each dialyzer over 3 weeks. Blood samples for several parameters will be collected during hemodialysis to assess the performance and hemocompatibility of the dialyzers under study. Data thus collected will be analyzed for comparison by standard statistical analysis.
Interventions
- DEVICE ELISIO-15H
- DEVICE Revaclear
- DEVICE Optiflux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433210
The ClinicalTrials.gov registry entry for NCT02433210 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ELISIO-15H is the first listed.
NCT02433210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02433210 about?
NCT02433210 is a clinical study titled "A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients". The aim of the study is to confirm the safety and clinical effectiveness of Nipro ELISIO-15H and to compare its performance characteristics and hemocompatibility with those of the commercially available dialyzers in U.S.A., Gambro Polyflux Revaclear and Fresenius F160NRe. 10 stable patients will be...
What is the current status of trial NCT02433210?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2015-06. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02433210?
The interventions under investigation include: ELISIO-15H (DEVICE), Revaclear (DEVICE), Optiflux (DEVICE).
Who is sponsoring clinical trial NCT02433210?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.